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Abstract
Screening for BRCA 1 and BRCA 2 mutations has long moved from the research lab to the clinic as a routine clinical
genetic testing. BRCA molecular alteration pattern varies among ethnic groups which makes it already a less
straightforward process to select the appropriate mutations for routine genetic testing on the basis of known
clinical significance.
The present report comprises an in depth literature review of the so far reported BRCA 1 and BRCA 2 molecular
alterations in Greek families. Our analysis of Greek cumulative BRCA 1 and 2 molecular data, produced by several
independent groups, confirmed that six recurrent deleterious mutations account for almost 60 % and 70 % of all
BRCA 1 and 2 and BRCA 1 mutations, respectively.
As a result, it makes more sense to perform BRCA mutation analysis in the clinic in two sequential steps, first
conventional analysis for the six most prevalent pathogenic mutations and if none identified, a second step of New
Generation Sequencing-based whole genome or whole exome sequencing would follow. Our suggested approach
would enable more clinically meaningful, considerably easier and less expensive BRCA analysis in the Greek
population which is considered homogenous.
Keywords: BRCA, Molecular alteration, Pathogenic mutation, Molecular genetic testing, Family/personal history,
Inherited breast cancer, Greece
Introduction
Breast cancer is the most common malignancy among
women in Greece involving 23 % of all types of cancers
[1]. According to World Health Organization ~87
women in a 100.000 Greek population will develop
breast cancer in their life time [2] with a relatively small
proportion of it to be classified as hereditary. Multiple
genes have been recognized to confer a risk of familial
breast cancer, but in more than 70 % of familial breast
cancer cases the genetic factor remains unclear. In the
remaining proportion, genetic testing can identify a
pathogenic mutation of BRCA 1 or BRCA 2 in more
than 25 % of the affected families while other known
genes namely TP53, PTEN, STK11, CHEK2, ATM may
account for no more than 1 % of the total familial breast
cancer [2, 3]. The inheritance of a deleterious mutation
in one of the two breast cancer susceptibility genes,
BRCA 1 and 2 , is associated with a high lifetime risk of
breast cancer, currently estimated at 65 % (CI 44-78 %)
for BRCA 1 and 45 % (CI:31-56 %) for BRCA 2 [3]. Dele-
terious mutations in BRCA genes also increase the life-
time risks of ovarian cancer and predispose to a range of
other malignancies.
It is widely accepted that the distinct differences in
cancer incidence and mortality observed among different
ethnic groups may appear due to ethnic background
dependent variant genetic component associated with the
disease combined to other non-genetic, epidemiologic and
life style connected risk factors. It is also documented that
different mutations concerning specific predisposition
gene(s), in our case BRCA 1 and BRCA 2, may
characterize different ethnic populations. Inherited gene
alterations which persistently appear from generation to
generation in specific ethnic groups can characterize those
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groups/populations and constitute what is known as
founder effect, which apparently is due to a shared com-
mon ancestry [4]. According to the literature, the founder
effect is the reduction in genetic variation or a gene muta-
tion observed in high frequency in a specific population
(add reference). Thus, it makes sense from the clinical
point of view to retrospectively analyze cumulative BRCA
molecular data for BRCA alterations confined to the
Greek population, which is considered over 95 % genetic-
ally homogeneous. Ultimately, this might help in develop-
ing a meaningful, comprehensive and cost-effective BRCA
diagnostic and prognostic tool to be offered to high-risk
individuals or breast/ovarian cancer patients [5].
BRCA 1 and BRCA 2 genes normally produce tumor
suppressor effect and it is commonly accepted that their
germline mutations account for the majority of the iden-
tified and diagnosed familial and hereditary breast and
ovarian cancers [6, 7]. Breast cancer attributed to BRCA
1 and BRCA 2 mutations tend to appear in younger age
and exert a more aggressive phenotype [8, 9]. Thus, gen-
etic testing for predisposition to breast cancer before the
spring of the disease and a more accurate molecular
diagnosis are both essential in applying preventive mea-
sures to individuals at risk and, for women with cancer,
patient stratification towards a more personalized med-
ical treatment in the long run. In this context, genetic
testing for BRCA 1 and BRCA 2 is recommended to
breast cancer patients diagnosed before age of 50, with
bilateral breast cancer, and/or triple negative breast can-
cer, and/or history of ovarian cancer, and/or more than
two first degree relatives with breast or ovarian cancer.
Following a positive for mutation diagnosis, other affected
and unaffected members of the family are screened for the
specific mutation. Genetic testing should also be con-
sidered for women with distinct family history of breast
and/or ovarian cancer where affected relatives cannot
be screened [10, 11].
Despite the extensive BRCA mutation screening of
Greek patients and individuals at risk, there is not yet
clear consensus as to what should be the most clinically
appropriate BRCA 1 and BRCA 2 mutation panel for the
Greek population. The present report constitutes a thor-
ough analysis of the so far identified mutations in Greek
families aimed to contribute to the real need to develop
a standard and comprehensive BRCA routine molecular
test in the clinic.
Methods
We conducted a PubMed literature inquiry using as key
words: Greek/breast cancer and genetics, which resulted
in 99 studies. We then reviewed all papers reporting
BRCA 1 and/or BRCA 2 molecular alterations and muta-
tions in the Greek population and we found that only 14
of the total 99 studies were originally designed to solely
include Greek families and patients. Cumulative Greek
family data were collected and analyzed for the pur-
pose to more precisely correlate, and perhaps associate
specific BRCA 1 and 2 mutations to the Greek ethnic
group.
Results - review
Currently, the exact proportion of breast cancer in
Greece with documented genetic component cannot be
accurately predicted, but it is believed to be comparable
to the European rates. For the BRCA 1 and 2 genes in
particular, which have long gained the attention of the
global bio community, a large amount of Greek (resident
within Greece or Greek-immigrant families) and Greek-
Cypriot data have been produced. Cumulative Greek
BRCA mutation data are shown in Table 1.
Historically, the first reported study in a Greek popula-
tion by Konstantopoulou et al. (appeared in the literature
in 2000) examined for BRCA 1 mutations 30 breast/ ovar-
ian cancer patients with strong or moderate family history
and premenopausal age at onset of the disease [12]. Three
mutations previously described in non-Greek populations,
(3741insA, 1623del5-TTAAA, 5382insC) and two novel
ones (3099delT, 3277insG) were found. This finding was
the first evidence that BRCA 1 mutations may account for
as much as 20 % of high-risk Greek families, incidence
comparable to other European countries. This was also
the first report correlating two novel mutations to the
Greek population. Later, in 2003, Kroupis et al. reported a
family affected with atypical medullary breast carcinoma
carrying the 5382insC mutation and thus confirmed that
this rather universal BRCA 1 mutation is detected in
Greece too [13]. Later, the exact same mutation was found
to be the most frequent mutation in Greek breast/ovarian
cancer families [14]. Ladopoulou et al. examined eighty
five patients with positive family history for BRCA 1 and
BRCA 2 deleterious mutations and 14 were found to carry
6 mutations: the aforementioned 5382insC, the non-sense
R1751X and the 5586G > A of BRCA 1, and frameshifts
2024del5, 3034del4, and 6631del5 of BRCA 2. Molecular
alterations of yet unknown biological significance including
some with higher than 1 % frequency and thus potentially
constituting polymorphisms were also reported.
Armaou et al. studied 95 patients of Northern Greece,
for BRCA 1 molecular alterations. Four deleterious dele-
tions in exons 20 and 24 were found in this study, one of
which was reported to be novel. There were two carriers
of that newly identified mutation; one developed breast
cancer at 28 years, ovarian cancer at 31 and endometrioid
cancer at 38 and the second carrier developed ovarian
cancer at 52 and breast cancer at 53 years. Hence, this
mutation is a strong candidate to be included in the Greek
BRCA 1 mutation panel to diagnose women with high risk
to develop early onset breast and ovarian cancer [15].
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Table 1 BRCA 1 and BRCA 2 mutations found in a Greek population. (Mutations repeatedly found in multiple papers share the same font colors)
Author Pathogenic mutation Sample/methods used Results
BRCA1 BRCA2
Konstantopoulou et al., 2000 [12] 3741insA, 1623del5-TTAAA 30 breast/ovarian cancer pts
with family history




Armakolas et al., 2002 [18] 2024del5 3058delA 6024del TA 4147del G 55 bc pts: 27 with family
history,28 sporadic bc
4 different mutations in 5 pts
SSCP, sequencing
Ladopoulou et al. 2002 [14] 5382insC non-sense R1751X 5586G > A 2024del5 3034del4 6631del5 85 pts with positive history Mutations in 14 families
(16.5 %)
PTT, SSCP, direct sequencing
Kroupis et al., 2003 [13] 5382insC Study of one affected family,
Belogianni et al., 2004 [16] exon 20: 5331G > A, 5382insC , entire exon 20
deletion exon 23:5586 G > A
25 individuals of 18 fms/12
high risk
5 fms were positive for
mutation
dHPLC, MLPA, Long PCR
Kataki et al., 2005 [19] 2306A > T, 4750C > A, 5129A > C, 5627G > T, IVS8-
19delT, 2196G > A, 4793A > G, 4956A > G,
4610 T > C
4147delG (2 pts), 3058delA, 6024delTA,
2024del5, 385A > G, 360 T > G
94 individuals with low or
moderate risk to be carriers
BRCA1: 5 unclassified variants
& 4 polymorphisms BRCA 2: 5
unclassified variants & 1
polymorphismPTT, SSCP , sequencing
Armaou et al., 2007 [15] exon 20:71146-75319del, 71618-74863del exon
24:82651-87079del, 82651-87079del
95 pts with positive family history (one case of sporadic Ca)
QMPSF, diagnostic PCR primers
Anagnostopoulos et al., 2008 [20] 5331G > A (G1738R) 287 breast/ovarian cancer families Study specific for G1738R
mutation/PCR sequencing
Konstantopoulou et al., 2008 [21] exon 20: 5382insC, 5331G > A (G1738R) 3058delA 2024del5 127 bc/ovarian cancer fms 16 fms BRCA1 mut & 5 fms
BRCA2 mut
diagnostic PCR primers, dHPLC
Armaou et al. 2009 [23] c.5266dupC, G1738R, and two deletions of exons
20 and 24
987 unselected pts examined
for specific mutations
2.6 % carriers
diagnostic PCR primers, PCR
Koumpis et al. 2011 [22] exon 20: 5331G > A, 3.2 kb deletion exon 11:
3819delGTAAA
exon 11: 3782del10, 4512insT 127 unselected sporadic bc
patients
6 carriers found (no family
history)
diagnostic PCR primers, PCR,
ABI, PTT
Pertesi et al. 2011 [24] exon 20:del D17S579 - D17S1299 (3.9 Mb) exon
24: del D17S951 , D17S1299 (2.9 Mb)
Study of affected families
diagnostic PCR primers (10 short tandem repeat markers)













Table 1 BRCA 1 and BRCA 2 mutations found in a Greek population. (Mutations repeatedly found in multiple papers share the same font colors) (Continued)
Konstantopoulou et al. 2014 [26] exon 5: (300 T > G - C61G) exon 7: (449delG-
ter118)* exon 11: (1329insCT)*, (1623del5),
(1624 T > G - L502X)*, (1806C > T - Q563X)*,
(2072del4), (2767insGGCA)*, (3082C > A - S988X)*
,(3297G > T - E1060X), (3494delTC), (3726C > T -
R1203X), (3741delA)*, (3819del5), (3874del4) exon
12: (4286delTG)* exon 14: (4510delCTAinsTT)
exon20: (5331G > A - G1738R), (5370C > T -
R1751X), (5382insC), (g.71660_74860del3200)
exon 21: (5447delC) exon 22: (IVS22 + 5G > C)
exon 23: (5550C > T -Q1811X)*, (5586G > A),
(g.80280_91331del11052) exon24: (5611delC),
(g.82651_87079del4429_ins5)
exon8- (886delGT) exon 11: (2567C > G -
S780X), (3036del4), (4643del4), (4997delA),
(5950delCT), (6718C > T - Q2164X), (6828delTT)
exon 17: (IVS16-2A > T)*, (8204G > A) exon 19:
(8592G > A - W2788X) exon 22: (9158delA)
exon23: (9218del32) exon 24: 9325insA exon
25: 9604C > T - Q3126X) exon 27: (9976insT)
473 breast/ovarian cancer
patients with family history
32 % mutation prevalence. 44
mutations found (6 BRCA1
recurrent/founder mutations
dominate the observed
spectrum-58.5 % of all
mutations found)
diagnostic PCR primers, direct
sequencing , MLPA
(pts patients, bc breast cancer, fms families, mut mutation)
PTT Protein truncation test
SCCP Single-Strand Conformation Polymorphism Analysis
dHPLC denaturing High Performance Liquid Chromatography
MLPA Multiplex Ligation – dependent PCR Amplification
QMPSF Quantitative Multiplex PCR of Short Fluorescent Fragments
ABI, TaqMan Copy Number Variation Assays













In another study, limited in Greece and Cyprus, 18 af-
fected families examined for BRCA 1 mutations and four
different mutations were found in five families : Muta-
tion 5382insC in exon 20, missense mutation 5331G > A
in exon 20 , single base substitution G > A at nucleotide
5586 in exon 23 and a first reported deletion of the en-
tire exon 20 [16]. Also, it is worth mentioning that these
mutations were associated to early onset breast cancer
(occurring in 29 to 50 years) with variable penetration.
Ovarian cancer presented in only one patient and there
were also cases of colorectal, larynx and lungs neoplasms
within these families, a pattern that resembles to Li
Fraumeni cancer syndrome. The deletion of the entire
exon 20 was identified in one Greek family and in one
Italian family generated from different DNA alterations.
Two unaffected mutation carriers aged 39 and 55 were
diagnosed, suggesting that calculating genetic risk based
on BRCA 1 alone may in fact be less informative than
we currently think [17].
In 2002, the first study with Greek BRCA 2 mutations
in breast cancer patients was published [18]. Armakolas
et al. examined five distinct breast cancer families, and
found one carrying the known germline deleterious mu-
tation (2024del5) and three other families carrying novel
mutations (3058delA, 6024delTA, and 4147delG). It is
noteworthy that breast cancer patients with tumors car-
rying these mutations exhibited more favorable clinical
phenotype compared to stage matched sporadic cases,
irrespective of histological type. Also, it was observed
that in a Greek population, this more favorable pheno-
type was correlated to a cluster of novel mutations in
exons 10 and 11 [18].
Following, Kataki et al. examined 94 individuals with
low or moderate risk for BRCA 1 and 2 mutations based
purely on family history [19]. Three novel BRCA1 mis-
sense mutations, one novel BRCA 1 intronic deletion,
three BRCA 2 truncating mutations, and one novel BRCA
2 missense mutation were identified.
According to the results of Anagnostopoulos et al.
study, which involved 11 Greek families residents of
Greece, Australia and USA, one missense mutation at
5331G > A of exon 20, accounts for 3 % and 12.3 % of all
breast/ovarian cancer families and all carriers of deleteri-
ous mutations, respectively [20]. These results coupled
to genealogical history, point to 5331G > A mutation as
a likely Greek founder effect. Not surprisingly, our analysis
confirmed that the most common pathogenic BRCA 1
mutation in the Greek population is the 5382insC located
also in exon 20, widely known as the Jewish founder,
which remains to be the most common (10 % of all BRCA
1 mutations) alteration amongst Caucasians worldwide,
and therefore, can be associated with the Caucasian race
[21]. Alternatively, our analysis further supports the view
that 5382insC is not an ethnic-specific characteristic but
rather a “universal” Caucasian mutation. Unlike 5382insC,
evidence indicates that the BRCA 2 mutations subst G>A
5586 in exon 23 for BRCA 1 and 2024del5 and 3058delA
can be considered as Greek-specific mutations [21].
Koumpis et al. [22] examined unselected by family his-
tory, breast cancer patients and six mutations were found
(four in BRCA 1 and two in BRCA 2) which account for
4.7 % of the total and for 9.5 % of cases diagnosed before
age forty. This result that breast cancer incidence doubles
before the age of forty adds to the current belief of strong
genetic component of early breast cancer onset. Recently,
we have also published a series of breast cancer in women
aged 25 years and younger where, the percentage of BRCA
mutations raised to 25 % of cases in this very young age
group. The overall incidence of BRCA mutations found in
Koumpis study is twice that found by Armaou et al. who
studied only four selected mutations in Greek women with
breast cancer [23] but in line with results published by
others having studied non Greek ethnic background
women. Notably, Koumpis et al. reported that only one of
the six mutation carriers reported family history of breast
or ovarian cancer, which strongly favors the current belief
that many carriers share no previous family history of the
disease. Taken together, the above data clearly indicate
both, that other than the aforementioned BRCA mutations
play a role in inherited Greek breast cancer and that breast
cancer susceptibility may involve other than the BRCA
genes, consistent with the results published by Inter-
national breast and ovarian cancer genetic predisposition
consortia (http://www.ncbi.nlm.nih.gov/pubmed/25581431
and http://www.ncbi.nlm.nih.gov/pubmed/25452441.
Before us, Koumpis et al. supported the view that mu-
tation 5331G > A of exon 20 is likely to be founder effect
in the Greek population [22]. In the same study, two
novel BRCA 1 mutations, one 3.2 kb deletion in exon 20
and one in exon 11 (3819delGTAAA) and two BRCA 2
mutations in exon 11 (3782del10, 4512insT), were found.
In addition, Pertesi et al. supported the view that the de-
letions of 3.9 Mb of exon 20 and 2.9 Mb of exon 24 may
be Greek ethnic group-associated molecular events [24].
Furthermore, Fostira et all described the p.E1060X ag-
gressive mutation in BRCA 1/exon 11 (c.3178G > T) that
affected a young woman with no family history. The in-
heritance proved to originate from the paternal family
that counted very few female members, fact which high-
lights the necessity of genetic testing even in cases with
negative family history [25].
In a recent study, Konstantopoulou et al. [26] conducted
a large survey screening 473 Greek breast/ovarian cancer
families for BRCA 1 and BRCA 2 mutations. This study
resulted in 28 different deleterious BRCA 1 mutations
(9 novels, firstly identified) and 16 deleterious BRCA 2
mutations (7 novels) which apparently set the basis for
the development of a diagnostic tool applicable to diagnose
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Greek familial breast/ovarian cancer. Interestingly, the
great majority (up to 75 %) of the BRCA 1 families were
positive for mutations located at the 3’end of the gene that
include exons 20 to 24. Alternatively, almost 60 % of all
Greek familial breast/ovarian cancer appear to be attribut-
able to BRCA 1 mutations in the same region of the gene
which, understandably, can streamline the whole mutation
analysis process.
It has been now two decades of intense research tar-
geted to BRCA 1 and 2 mutations covering a wide range
of different ethnic populations. Most of the Greek stud-
ies cited here have predominantly focused on examining
families with positive history in accordance with the
current guidelines which recommend focusing BRCA
genetic screening on unaffected members of affected
families [27]. We now know that this biased approach
towards breast cancer cases selected on a family history
basis, has provided limited information as per the actual
prevalence of BRCA 1 and 2 mutations in the Greek
population and the actual penetrance of the disease in
carriers. Moreover, increasing evidence indicates that a
large fraction of families with a strong family history of
breast cancer scores negative for BRCA mutations which
underlines the importance to always make a clear dis-
tinction between familial and inherited breast cancer, the
former being a small subset of the latter. New genes, like
PALB 2, are likely to emerge as the next breast cancer
susceptibility gene(s) and their screening will gradually
intensify, beyond any doubt [8]. However, this accumula-
tive data confirms that in a homogenous ethnic popula-
tion like Greek, common BRCA mutations can facilitate
genetic testing.
Conclusions
Considerable effort has been made to detect and more ac-
curately predict the BRCA 1 and 2 mutations with the
highest frequency in the homogeneous Greek population.
Our analysis of cumulative Greek BRCA data clearly indi-
cates that six specific mutations account for almost 60 %
of BRCA 1 and 2 mutations and 70 % of BRCA 1 muta-
tions. This observation strongly supports the view that a
two-step BRCA analysis procedure might be more mean-
ingful to be implemented in the Greek clinic. In other
words, in clinical routine, every Greek woman referred for
BRCA screening can undergo screening for the six known
mutation first and if the first step fails to diagnose a
deleterious mutation, then a comprehensive New Gen-
eration Sequencing-based whole genome or whole exon
analysis, as previously described by others (indicatively,
http://www.ncbi.nlm.nih.gov/pubmed/25859162 and
http://www.ncbi.nlm.nih.gov/pubmed/25896959) will
follow. Only after BRCA genetic testing of tens of thou-
sands of Greek women will have been completed, we will
be in a position to more accurately evaluate whether the
suggested six mutation panel is the appropriate one or
needs to be extended and/or changed for the purpose of
the daily routine BRCA testing in the clinic and whether
one or more of these or new mutations may constitute a
Greek founder effect.
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